DWP14012 is an investigational drug.
There have been 24 clinical trials for DWP14012.
The most recent clinical trial was a Phase 3 trial, which was initiated on June 2nd 2020.
The most common disease conditions in clinical trials are Esophagitis, Gastroesophageal Reflux, and Esophagitis, Peptic. The leading clinical trial sponsors are Daewoong Pharmaceutical Co. LTD., Sun Young, Kim, and Hanyang University.